Supreme Court questions silence over costly cancer medicines
The Supreme Court has criticised what it described as excessive pricing of essential cancer medicines, calling the situation “broad daylight dacoity”. The Bench also expressed surprise that authorities responsible for acting on the issue had remained silent, according to The Hindu’s report.
The Supreme Court has sharply questioned the pricing of essential cancer medicines, describing the situation as “broad daylight dacoity”, according to The Hindu. The Bench said it was surprised that authorities expected to take action against the alleged overpricing had not acted. “It is very surprising that the authorities who are supposed to take action on this are silent,” the Bench said.
The source material does not identify the medicines involved, the authorities referred to, or any directions issued by the court. It also does not provide details of the pricing under examination or the response of the parties concerned. The remarks place the affordability of essential cancer treatment and the role of regulatory authorities at the centre of the proceedings.
This independently written report is based on information supplied by the named publisher. Vertrix News has not independently verified the source report.